Clinical Trials Logo

Refractory Ovarian Carcinoma clinical trials

View clinical trials related to Refractory Ovarian Carcinoma.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT04753216 Completed - Clinical trials for Recurrent Ovarian Carcinoma

Irinotecan Liposome and Bevacizumab for the Treatment of Platinum Resistant, Recurrent, or Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Start date: March 16, 2021
Phase: Phase 2
Study type: Interventional

This phase II trial investigates the effect of irinotecan liposome and bevacizumab in treating patients with ovarian, fallopian tube, or primary peritoneal cancer that shows less response to platinum therapy (platinum resistant), has come back (recurrent), or does not respond to treatment (refractory). Irinotecan liposome may help block the formation of growths that may become cancer. Bevacizumab is a monoclonal antibody that may interfere with the ability of tumor cells to grow and spread. Giving irinotecan liposome and bevacizumab may kill more cancer cells.

NCT ID: NCT03784677 Completed - Clinical trials for Advanced Malignant Solid Neoplasm

A Phase I Study of SOR-C13 in Patients With Advanced Solid Tumors

Start date: July 29, 2019
Phase: Phase 1
Study type: Interventional

This phase I trial studies the side effects and best dose of SOR-C13 in treating patients with solid tumors that have spread to other places in the body (advanced) and does not respond to treatment. Drugs used in chemotherapy, such as SOR-C13, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.

NCT ID: NCT03756818 Completed - Clinical trials for Advanced Malignant Solid Neoplasm

TAK-659 and Paclitaxel in Treating Patients With Advanced Solid Tumors

Start date: March 5, 2019
Phase: Phase 1
Study type: Interventional

This phase I trial studies the best dose and side effects of TAK-659 and paclitaxel in treating patients with advanced solid tumors. TAK-659 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving TAK-659 and paclitaxel may work better in treating patients with advanced solid tumors.